MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-02-2026
AngioDynamics General and Administrative Expenses 2011-2026 | ANGO
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses AngioDynamics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.1 M | 41.2 M | 40 M | 38.5 M | 35.9 M | 37.9 M | 34.9 M | 31.3 M | 31.4 M | 29.6 M | 29.9 M | 26 M | 26.1 M | 18.3 M | 17.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 42.1 M | 17.8 M | 32.1 M |
Quarterly General and Administrative Expenses AngioDynamics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.7 M | 12.6 M | - | 10.5 M | 10.4 M | 11 M | - | 10.6 M | 9.29 M | 10.9 M | - | 8.84 M | 10.8 M | 10.1 M | 20.9 M | 8.73 M | 9.68 M | 8.94 M | 18.6 M | 9.01 M | 9.22 M | 8.56 M | 9.22 M | 8.56 M | 11 M | 8.45 M | 11 M | 8.45 M | 9.26 M | 8.44 M | 9.34 M | 8.5 M | 7.54 M | 8.06 M | 7.54 M | 8.06 M | 7.84 M | 8.2 M | 7.78 M | 8.17 M | 8.08 M | 7.91 M | 8.09 M | 7.43 M | 7.79 M | 7.32 M | 7.97 M | 7.32 M | 6.41 M | 6.69 M | 6.32 M | 6.53 M | 6.91 M | 6.9 M | 6.91 M | 4.43 M | 4.62 M | 4.31 M | 4.62 M | 4.31 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.9 M | 4.31 M | 8.69 M |
General and Administrative Expenses of other stocks in the Medical instruments industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
23.2 K | - | - | $ 810 M |  USA |
 |
The Cooper Companies
COO
|
1.63 B | $ 68.58 | -0.06 % | $ 13.7 B | USA |
 |
Glaukos Corporation
GKOS
|
332 M | $ 124.9 | -1.21 % | $ 7.14 B | USA |
 |
Luminex Corporation
LMNX
|
140 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
3.73 M | - | -9.52 % | $ 20.6 M | USA |
 |
Intuitive Surgical
ISRG
|
2.38 B | $ 425.07 | -0.36 % | $ 152 B | USA |
 |
Alcon
ALC
|
251 M | $ 67.23 | -0.99 % | $ 40.4 B |  Schweiz |
 |
ICU Medical
ICUI
|
625 M | $ 144.38 | 1.68 % | $ 3.56 B | USA |
 |
Repro Med Systems
KRMD
|
23.4 M | $ 4.03 | 0.75 % | $ 186 M | USA |
 |
iRhythm Technologies
IRTC
|
493 M | $ 116.7 | 2.52 % | $ 3.73 B | USA |
 |
LeMaitre Vascular
LMAT
|
42 M | $ 97.43 | 0.87 % | $ 2.21 B | USA |
 |
Masimo Corporation
MASI
|
744 M | $ 179.95 | - | $ 9.59 B | USA |
 |
Microbot Medical
MBOT
|
8.46 M | $ 1.83 | 0.77 % | $ 83.8 M |  Israel |
 |
Antares Pharma, Inc.
ATRS
|
62.8 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
198 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
8.44 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
941 M | - | -0.05 % | $ 10.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
9.99 M | - | - | $ 28.6 M | USA |
 |
Milestone Scientific
MLSS
|
11.6 M | $ 0.39 | -0.31 % | $ 32 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
671 M | - | -0.02 % | $ 16.3 B | USA |
 |
Merit Medical Systems
MMSI
|
455 M | $ 67.96 | 0.67 % | $ 4.02 B | USA |
 |
electroCore
ECOR
|
38.2 M | $ 9.52 | - | $ 80.8 K | USA |
 |
Envista Holdings Corporation
NVST
|
1.16 B | $ 24.48 | -0.45 % | $ 4.11 B | USA |
 |
Haemonetics Corporation
HAE
|
442 M | $ 79.66 | 1.17 % | $ 3.76 B | USA |
 |
STERIS plc
STE
|
1.41 B | $ 212.15 | -0.28 % | $ 20.8 B | USA |
 |
Isoray
ISR
|
30.2 M | - | 0.03 % | $ 108 M | USA |
 |
STAAR Surgical Company
STAA
|
85.8 M | $ 29.97 | 0.33 % | $ 1.49 B | USA |
 |
InfuSystem Holdings
INFU
|
57 M | $ 9.03 | 0.22 % | $ 187 M | USA |
 |
Teleflex Incorporated
TFX
|
720 M | $ 134.56 | -0.88 % | $ 6 B | USA |
 |
Utah Medical Products
UTMD
|
7.88 M | $ 68.07 | - | $ 221 M | USA |
 |
West Pharmaceutical Services
WST
|
394 M | $ 332.82 | -0.63 % | $ 24.1 B | USA |
 |
Pulse Biosciences
PLSE
|
32 M | $ 25.25 | -2.04 % | $ 1.7 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.44 B | $ 10.45 | -0.19 % | $ 2.08 B | USA |
 |
Retractable Technologies
RVP
|
12.8 M | $ 0.69 | -0.03 % | $ 20.7 M | USA |
 |
Pro-Dex
PDEX
|
4.84 M | $ 65.09 | 0.14 % | $ 214 M | USA |
 |
Predictive Oncology
POAI
|
25.9 M | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
45.5 M | $ 28.02 | 1.71 % | $ 1.34 B | USA |
 |
Stereotaxis
STXS
|
17.8 M | $ 1.83 | -1.08 % | $ 166 M | USA |
 |
Baxter International
BAX
|
2.89 B | $ 20.34 | 1.55 % | $ 10.4 B | USA |
 |
ResMed
RMD
|
739 M | $ 196.36 | -0.32 % | $ 28.7 B | USA |
 |
AtriCure
ATRC
|
311 M | $ 27.78 | 1.74 % | $ 1.33 B | USA |
 |
Harvard Bioscience
HBIO
|
17.7 M | $ 6.15 | 1.82 % | $ 273 M | USA |
 |
NeuroMetrix
NURO
|
6.33 M | - | 5.05 % | $ 9.02 M | USA |
 |
Becton, Dickinson and Company
BDX
|
5.28 B | $ 151.46 | -0.39 % | $ 43.6 B | USA |
 |
Nephros
NEPH
|
9 M | $ 3.19 | -1.82 % | $ 33.9 M | USA |
 |
OraSure Technologies
OSUR
|
47.7 M | $ 4.27 | 0.71 % | $ 314 M | USA |
 |
Repligen Corporation
RGEN
|
291 M | $ 133.39 | 2.51 % | $ 7.5 M | USA |